AAV- based vector improvements unrelated to capsid protein modification

Area of Science:

• Molecular Biology
• Gene Therapy
• Virology

Background:

• Recombinant adeno-associated virus (rAAV) is a primary vector for in vivo genetic material delivery.
• Three rAAV-based gene therapies are FDA-approved, highlighting their clinical significance.
• Further improvements in rAAV vectors are necessary for broader therapeutic applications.

Purpose of the Study:

• To review strategies for enhancing rAAV vector performance.
• To focus on modifications beyond capsid proteins, specifically ITRs, transgene cassettes, and Rep proteins.
• To discuss how these modifications impact AAV production and transduction efficiency.

Main Methods:

• Review of existing literature on rAAV vector engineering.
• Analysis of the roles of inverted terminal repeats (ITRs) in viral replication and encapsidation.
• Examination of the function of Rep proteins in the AAV life cycle.
• Assessment of transgene cassette design in relation to vector production and gene expression.

Main Results:

• Capsid protein modifications are common, but ITRs, transgene cassettes, and Rep proteins also significantly influence AAV biology.
• Rep proteins and ITRs are critical for viral genome replication and encapsidation.
• Transgene cassette expression directly correlates with AAV production and transduction efficiency.

Conclusions:

• Modifying ITRs, transgene cassettes, and Rep proteins offers significant potential for improving rAAV vector efficacy.
• Targeted engineering of these non-capsid elements can enhance gene therapy outcomes.
• Further research into these components will advance the development of next-generation rAAV gene therapies.